Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: Effect on biochemical markers of bone metabolism and bone mineral density

Menopause

Volumn 7, Issue 5, 2000, Pages 318-326

  Miller, B E ^a   De Souza, M J ^a   Slade, K ^a   Luciano, A A ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Bone markers; Bone metabolism; Bone mineral density; HRT; Menopause; Micronized hormones

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CREATININE; DEOXYPYRIDINOLINE; ESTRADIOL; FOLLITROPIN; PROGESTERONE; TESTOSTERONE;

ABSORPTIOMETRY; ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; ENZYME BLOOD LEVEL; FEMALE; HIP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPINE; URINE LEVEL;

EID: 0033857336     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200007050-00006     Document Type: Article

References (49)

1. Postmenopausal osteoporosis
2. Hormone replacement therapy in postmenopausal women
3. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women
4. The minimum effective dose of estrogen for prevention of postmenopausal bone loss
5. Estrogen replacement therapy I. A 10-year prospective study on the relationship to osteoporosis
6. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis
7. A comparison of the effect of synthetic and micronized hormone replacement therapy on bone mineral density and biochemical markers of bone metabolism
8. Oral micronized therapy using 17-beta micronized estradiol: A preliminary study of effectiveness, tolerance and patient preference
9. Micronized 17 β-estradiol for oral estrogen therapy in postmenopausal women
10. Low-dosage micronized 17-β estradiol prevents bone loss in postmenopausal women
11. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women
12. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 β-estradiol
13. Sublingual absorption of micronized 17 β-estradiol
14. Oral micronized progesterone
15. Oral administration of micronized progesterone: A review and more experience
16. Clinical evaluation of near continuous oral micronized progesterone therapy in estrogenized postmenopausal women
17. The postmenopausal estrogen/progestin interventions trial (PEPI): Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women
18. A longitudinal study of the effects of menopause on sexuality
19. Sexuality in the climacteric
20. Androgens and the postmenopausal woman
21. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
22. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: Effects on bone mineral density, symptoms and lipid profiles
23. Identification of androgen receptors in normal human osteoblast-like cells
24. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women
25. Androgens directly stimulate proliferation of bone cells in vitro
26. Androgen receptors in osteoblast cell lines
27. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipidlipoprotein profiles in surgical menopause
28. Androgens
29. Liver function on postmenopausal women on estrogen-androgen hormone replacement therapy: A meta-analysis of eight clinical trials
30. Estrogen-androgen hepatotoxicity?
31. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature, 1941-1996
32. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy
33. Clinical use of biochemical markers of bone remodeling in osteoporosis
34. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients
35. Concurrent assays of bone Gla-protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease
36. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants
37. Progesterone as a bone trophic hormone
38. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen
39. A randomized double-blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone
40. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis
41. Cyclic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances
42. Premenopausal ovariectomy-related bone loss: A randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate
43. Short-term effects of high dose oral medroxyprogesterone acetate on-bone mineral density in postmenopausal women
44. Lack of effect of short-term micronized progesterone on bone turnover in postmenopausal women
45. The lack of effect of progesterone on bone
46. The postmenopausal estrogen/progestin interventions trial (PEPI): Effects of hormone therapy on bone mineral density